Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030965 · ClinicalTrials.gov registry record · Phase 2
28-day Repeat Dose Study of GSK573719
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 285
- Enrollment target
NCT01030965: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT01030965 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 285 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (114% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01030965, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 285 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD
Primary Outcome
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 29 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after dosing on Day 28. Baseline is defined as the mean of the FEV1 values obtained at 30 minutes and immediately pre-dose on Day 1. Change from Baseline is defined as the difference between trough on Day 29 and Baseline. Analysis was performed using a repeated measures mo
Interventions
- DRUG Placebo
- DRUG GSK573719 125mcg
- DRUG GSK573719 250mcg
- DRUG GSK573719 500mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2009-12-15 |
| Est. Completion | 2010-07-04 |
| Phase | Phase 2 |
What the finished NCT01030965 record still lists
NCT01030965 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (114% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01030965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01030965 about?
NCT01030965 is a clinical study titled "28-day Repeat Dose Study of GSK573719". The study will evaluate the efficacy, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD
What is the current status of trial NCT01030965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2009-12-15. Estimated completion is 2010-07-04.
What interventions are being tested in trial NCT01030965?
The interventions under investigation include: Placebo (DRUG), GSK573719 125mcg (DRUG), GSK573719 250mcg (DRUG), GSK573719 500mcg (DRUG).
Who is sponsoring clinical trial NCT01030965?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01030965's enrollment target sits among peer trials
285 192nd of 2000 higher than 1,806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03412877 · 285 participants · Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- NCT04537936 · 285 participants · NA
Psychotherapy Intervention for Latinos With Adv Cancer
- NCT04965675 · 285 participants · Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- NCT05320835 · 285 participants · NA
A Setting Focus Overdose Prevention Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI